Maker of medical devices and tissue products for cardiac and vascular surgery, including heart valves, stent grafts and preserved tissue.
Maker of medical devices and tissue products for cardiac and vascular surgery, including heart valves, stent grafts and preserved tissue.
Formerly CryoLife, it was renamed Artivion in 2022 after building out aortic products, notably the JOTEC stent grafts bought in 2017. Sales go to hospitals through direct sales and distributors, while preserved human tissue is processed from donated tissue and shipped to surgeons.
Moat: narrow (regulatory licence, brand, installed base). Niche cardiac/vascular device and tissue-processing brands built over decades, though smaller-scale than majors.
Headquarters: Atlanta, Georgia · Founded: 1997 · Employees: 1,800
Size Artivion (AORT) is a United States Health Care company (Medical Specialties) with a market value of $905M, the 2294th largest of 3,085 United States companies the cockpit tracks. Shares closed at $18.54 on 18 Nov 2026.
Performance Over six months the shares fell 18.2%, against -12.1% for the median peer and -2.2% for the United States market (cap-weighted) — 8th lowest of 21 in its peer set.
Growth Revenue grew 14.0% over the last twelve months (peer median +6.0%); the operating margin is 4.9% (peer median 9.6%).
Valuation It trades at 383.6× forward earnings against a peer median of 21.7× (most expensive of 17).
Capital Return on invested capital runs 7.4 points below its cost of capital (9.7% WACC).
Short interest Short interest is 7.0% of the free float (30 Oct 2026).
Next results Next results expected around 18 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $482M | $441M | $389M | $354M | $314M |
| Revenue growth | — | +14% | +10% | +13% | — |
| Gross profit | $289M | $270M | $233M | $214M | $187M |
| EBITDA | $49.8M | $56.6M | $51.7M | $37.9M | $37.4M |
| Net income | -$17.6M | $9.76M | -$13.3M | -$30.6M | -$19.1M |
| Free cash flow | -$42.6M | $839,000 | $11.0M | $11.1M | -$14.2M |
| Capital expenditure | $59.3M | $39.0M | $11.2M | $7.43M | $10.7M |
| Total debt | $407M | $259M | $362M | $359M | $357M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Artivion AORT | $905M | -18% | +14% | 5% | 383.6× | n/a |
| Medtronic MDT | $129B | +30% | +10% | 20% | 16.8× | 9.1% |
| Edwards Lifesciences EW | $60.5B | +27% | +13% | 29% | 32.3× | 17.1% |
| Abbott Laboratories ABT | $181B | +18% | +10% | 14% | 17.9× | 16.5% |
| LeMaitre Vascular LMAT | $1.73B | -25% | +12% | 28% | 24.5× | 2.9% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | AORT | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -19.7% | -6.3% | 3rd lowest of 21 |
| 6-month return | -18.2% | -12.1% | 8th lowest of 21 |
| Distance from 52-week high | -61.6% | -38.6% | 2nd lowest of 21 |
| Revenue growth (TTM) | +14.0% | +6.0% | 8th highest of 21 |
| Operating margin | 4.9% | 9.6% | 5th lowest of 21 |
| Forward P/E | 383.6× | 21.7× | most expensive of 17 |
| ROIC minus cost of capital | -7.4 pp | +2.9 pp | 3rd lowest of 21 |
| EV / EBITDA | 25.3× | 9.9× | 3rd most expensive of 9 |
| Net debt / EBITDA | 7.2× | 0.3× | 2nd most indebted of 10 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Artivion AORT | United States | $905M | -18% | +14% | 5% | 383.6× | n/a | n/a |
| Kuros Biosciences KURN.SW | Switzerland | $907M | -12% | +41% | 6% | 70.5× | n/a | n/a |
| Bioventus BVS | United States | $895M | -3% | +4% | 10% | 13.0× | 7.5% | +12.1% |
| Aidite (Qinhuangdao) Technology 301580.SZ | China | $888M | -12% | +17% | 18% | 26.2× | 19.3% | +23.3% |
| Shenzhen YHLO Biotech 688575.SS | China | $882M | -16% | +3% | 12% | 30.7× | 2.0% | +12.7% |
| Hangzhou Biotest Biotech 688767.SS | China | $878M | -12% | -4% | 3% | 37.0× | n/a | n/a |
| Xiangyu Medical 688626.SS | China | $877M | -38% | 0% | 4% | 56.2× | n/a | n/a |
| Tinavi Medical Technologies 688277.SS | China | $872M | -36% | -2% | -59% | n/a | n/a | n/a |
| L&C BIO 290650.KS | South Korea | $943M | -37% | +65% | 20% | n/a | 32.6% | +21.0% |
| Menicon 7780.T | Japan | $944M | +26% | +6% | 9% | 20.9× | n/a | n/a |
| Beijing SDL Technology 002658.SZ | China | $864M | -34% | -13% | 9% | 22.4× | 16.8% | +2.9% |
| HOB Biotech 688656.SS | China | $858M | -33% | +6% | 7% | 166.9× | 37.6% | +12.4% |
| Safilo SFL.MI | Italy | $953M | +42% | -4% | 9% | 15.8× | 1.3% | +4.7% |
| Shantou Institute of Ultrasonic Instruments 301602.SZ | China | $858M | -25% | +4% | 30% | n/a | 11.1% | +4.6% |
| JINS 3046.T | Japan | $963M | -8% | +14% | 10% | 18.7× | -6.1% | +11.7% |
| Mani 7730.T | Japan | $965M | -7% | +10% | 30% | 19.9× | 3.3% | +13.9% |
| Modern Dental 3600.HK | Hong Kong | $844M | +24% | +12% | 22% | 8.5× | -7.1% | +11.3% |
| Cisen Pharmaceutical 603367.SS | China | $843M | -15% | -6% | 8% | 7.9× | -14.6% | -1.3% |
| Cofoe Medical Technology 1187.HK | Hong Kong | $836M | -11% | +40% | 10% | 13.1× | -6.4% | +6.6% |
| INKON Life Technology 300143.SZ | China | $985M | -23% | +22% | 12% | 50.3× | 10.7% | +12.9% |
| OrthoPediatrics KIDS | United States | $826M | +71% | +16% | -8% | n/a | n/a | n/a |